NextCure's 2025 Reverse Split Faces Court Challenge — Merger with Avere at Risk
NXTC has more than doubled off its 52-week low of $1.55.
Summary
NextCure is asking a Delaware court to validate its 2025 reverse stock split after discovering the vote may have fallen short of the required supermajority. An adverse ruling could jeopardize the pending Avere merger and the company's Nasdaq listing.
Key Events · Legal and Risk Events · NXTC
-
Section 205 Petition Filed
NextCure filed a petition in Delaware Chancery Court on September 14, 2026 seeking validation of its July 10, 2025 reverse stock split amendment and all shares issued in reliance on it.
-
Vote Fell Short of Supermajority
The 2025 reverse split received 18,166,577 votes for (64.76% of outstanding shares) and 2,028,946 against — below the 66 2/3% supermajority that may have been required under the company's charter.
-
Merger with Avere at Risk
An adverse ruling could delay or prevent completion of the proposed merger with Avere Therapeutics, which is expected to close in November 2026.
-
Court Hearing Scheduled
The Delaware Chancery Court will hold a hearing on the petition at 3:00 p.m. ET on November 6, 2026. Stockholders opposing the petition must file written submissions by October 27, 2026.
Analysis · NXTC · Life Sciences
NextCure disclosed that its July 2025 reverse stock split may have been invalid because it was approved by only 64.76% of outstanding shares, below the 66 2/3% supermajority that may have been required under its charter. The company filed a Section 205 petition in Delaware Chancery Court to validate the split and all shares issued since. A hearing is set for November 6, 2026 — just weeks before the expected November closing of the Avere Therapeutics merger. If the court rules against NextCure, the company's entire post-split capital structure could be called into question, potentially delaying or derailing the merger and threatening its Nasdaq listing. The filing also reveals that multiple financings — a Simcere subscription, a November 2025 PIPE, and a $14.5M ATM — were all executed in reliance on the split's validity, meaning an adverse ruling could unwind or complicate those transactions.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 37.1% of the 989 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.64%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NXTC was trading at $5.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.3M. The 52-week trading range was $1.55 to $15.74. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.